Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1989 2
1991 1
1993 1
1995 1
1996 1
1998 1
2000 4
2001 1
2002 2
2003 2
2004 3
2005 3
2006 2
2007 3
2008 6
2009 3
2010 1
2011 3
2012 1
2013 4
2014 1
2015 4
2016 3
2017 8
2018 3
2019 7
2020 2
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Malignant Oral Neoplasm"
Page 1
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, Plesner T, Moreau P, Gibbs SD, Coppola S, Yang X, Al Masud A, Ross JA, Bueno O, Kaufman JL. Bahlis NJ, et al. J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13. J Clin Oncol. 2021. PMID: 34388020 Free PMC article. Clinical Trial.
PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. ...Common adverse events with VenDd and VenDVd included diarrhea (63% and 54%) and nausea (50% and …
PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple mye …
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J. Bahleda R, et al. Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14. Clin Cancer Res. 2019. PMID: 31088831 Clinical Trial.
The most common treatment-related adverse events were hyperphosphatemia (64%), dry mouth (42%), and asthenia (28%), generally grade 1/2 severity. All cases of hyperphosphatemia were grade 1/2 except for 1 grade 3 event. Skin, nail, and eye changes were observed in 4 …
The most common treatment-related adverse events were hyperphosphatemia (64%), dry mouth (42%), and asthenia (28%), generally grade 1 …
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C. O'Cearbhaill RE, et al. Gynecol Oncol. 2023 Sep;176:16-24. doi: 10.1016/j.ygyno.2023.06.021. Epub 2023 Jul 5. Gynecol Oncol. 2023. PMID: 37418832 Clinical Trial.
High-throughput cell-based drug screening predicted activity of dasatinib, a tyrosine kinase inhibitor, in ARID1A-mutant clear cell carcinoma. METHODS: We conducted a phase 2 clinical trial of dasatinib 140 mg once daily by mouth in patients with recurrent or persis …
High-throughput cell-based drug screening predicted activity of dasatinib, a tyrosine kinase inhibitor, in ARID1A-mutant clear cell c …
Breast cancer prevention.
Russo J, Balogh G, Russo IH. Russo J, et al. Climacteric. 2007 Oct;10 Suppl 2:47-53. doi: 10.1080/13697130701606762. Climacteric. 2007. PMID: 17882673
We have developed a new approach for breast cancer prevention, capitalizing in the preventive effect of early first full-term pregnancy, hormonally induced differentiation and our ability to identify specific genomic signatures that allow us to predict risk reduction. Earl …
We have developed a new approach for breast cancer prevention, capitalizing in the preventive effect of early first full-term pregnancy, hor …
AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-kappaB activation in oral squamous cell carcinoma.
Chiu HW, Lee HL, Lee HH, Lu HW, Lin KY, Lin YF, Lin CH. Chiu HW, et al. J Transl Med. 2024 Jan 3;22(1):13. doi: 10.1186/s12967-023-04825-w. J Transl Med. 2024. PMID: 38166970 Free PMC article.
BACKGROUND: Radioresistance and lymph node metastasis are common phenotypes of refractory oral squamous cell carcinoma (OSCC). As a result, understanding the mechanism for radioresistance and metastatic progression is urgently needed for the precise management of …
BACKGROUND: Radioresistance and lymph node metastasis are common phenotypes of refractory oral squamous cell carcinoma (OSCC). …
Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
Alan-Selcuk N, Beydagi G, Demirci E, Ocak M, Celik S, Oven BB, Toklu T, Karaaslan I, Akcay K, Sonmez O, Kabasakal L. Alan-Selcuk N, et al. J Nucl Med. 2023 Oct;64(10):1574-1580. doi: 10.2967/jnumed.123.265546. Epub 2023 Aug 24. J Nucl Med. 2023. PMID: 37620050
Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [(225)Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; n = 19). .. …
Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patie …
Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
Paoletti C, Le Pecq JB, Dat-Xuong N, Juret P, Garnier H, Amiel JL, Rouesse J. Paoletti C, et al. Recent Results Cancer Res. 1980;74:107-23. doi: 10.1007/978-3-642-81488-4_15. Recent Results Cancer Res. 1980. PMID: 7003658 Review.
This compound administered at 80-100 mg/m2/week in 1-h intravenous (IV) infusion induces objective remissions in about 25% of patients suffering from advanced breast cancer refractory to all other treatment. These remissions, which occurred after 3-4 weeks, lasted for 1-18 …
This compound administered at 80-100 mg/m2/week in 1-h intravenous (IV) infusion induces objective remissions in about 25% of patients suffe …
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Damle NA, Shamim SA, Kumar R, Seth A, Bal C. Yadav MP, et al. PLoS One. 2021 May 10;16(5):e0251375. doi: 10.1371/journal.pone.0251375. eCollection 2021. PLoS One. 2021. PMID: 33970962 Free PMC article.
Patients re-treated with additional treatment options after attaining 177Lu-PSMA refractory disease showed a remarkably prolonged OS. A significant clinical benefit was achieved post 177Lu-PSMA-617 RLT. The most common toxicities observed were fatigue (34.7%), follo …
Patients re-treated with additional treatment options after attaining 177Lu-PSMA refractory disease showed a remarkably prolonged OS. …
Photodynamic therapy for extensive oral verrucous/granular leukoplakia with moderate-to-severe dysplasia: A case study.
Zhang Q, Wang F, Liang J, Kuang W, Zeng X, Zhang X. Zhang Q, et al. Photodiagnosis Photodyn Ther. 2022 Sep;39:102910. doi: 10.1016/j.pdpdt.2022.102910. Epub 2022 May 22. Photodiagnosis Photodyn Ther. 2022. PMID: 35613692
Non-homogeneous oral verrucous/granular leukoplakia is a potentially malignant disorder with a higher malignant transformation rate than homogeneous leukoplakia. Surgical resection is commonly performed since the disease is often malignant and refra …
Non-homogeneous oral verrucous/granular leukoplakia is a potentially malignant disorder with a higher malignant transfo …
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).
Kalff A, Khong T, Mithraprabhu S, Bergin K, Reynolds J, Bowen KM, Thakurta A, Guzman R, Wang M, Couto S, Ren Y, Spencer A. Kalff A, et al. Leuk Lymphoma. 2019 Sep;60(9):2143-2151. doi: 10.1080/10428194.2019.1571201. Epub 2019 Jun 11. Leuk Lymphoma. 2019. PMID: 31184224 Clinical Trial.
The MTD of CC-486 was 150 mg d1-21; recommended expansion dose was 100 mg d1-21. Adverse events were predictable and manageable. ORR was 37.5%; clinical benefit rate was 50%. ...CC-486, LEN and DEX produced meaningful clinical responses in heavily treated LEN refractory …
The MTD of CC-486 was 150 mg d1-21; recommended expansion dose was 100 mg d1-21. Adverse events were predictable and manageable. ORR …
73 results